Clinuvel Pharmaceuticals Limited

CLINUVEL said revenue exceeded AUD 100 million for the second year in a row, SCENESSE treatment volumes were up 6% year over year, European treatment volumes increased 13% and boosted European revenue by 9%, gross profit margin was 83%, and net profit margin was 36%. Cash reserves increased by AUD 28 million to AUD 252 million, total assets were AUD 295 million, and the company said it held about AUD 231 million in term deposits yielding 6.23%. Management said expenditure came in at AUD 53.5 million versus an earlier stated average target of AUD 55 million, and that AUD 4 million of reported EBIT impact came from an unrealized translation loss. No explicit next-quarter or full-year revenue/EPS guidance was provided; instead, management flagged Q4 top-line results for CUV105 and the start of CUV107, with CUV107 readout expected in 2029 after a planned November 2026 start and approximately 2 years of recruitment and follow-up. They also said the target of 190 trained accredited centers by 2027 is on track.

Philippe Wolgen framed the NASDAQ move as a maturity milestone and said the company needs to be where its current and future economic activity will be, especially in North America. He emphasized that CLINUVEL has long prepared for a U.S. listing, that most intellectual property sits outside Australia, and that the company wants a single listing so it can focus resources on one exchange. His tone was confident and dismissive of fears around competition and share-price volatility, which he said are normal in life sciences and should be viewed through objective valuation metrics.

Peter Vaughan stressed a disciplined model built around profitability, positive net cash flow, strategic investment, and putting surplus funds to work. He highlighted the AUD 28 million increase in cash reserves to AUD 252 million, total assets of AUD 295 million, and about AUD 231 million in term deposits earning 6.23%. He said the company remains debt-free for a 20th consecutive year, has not raised capital in 10 years, and that the reported AUD 4 million translation loss was non-economic. He also noted spend of AUD 53.5 million, including about AUD 8 million of CBM activity, and said the company reinvested 20% of revenue into R&D.

Analysts focused on vitiligo timing, pricing, FDA interaction, NEURACTHEL commercialization, EPP competition, and the controlled-release injectable peptide platform. Management said CUV107 starts in November 2026, runs about 2 years, and reads out in 2029; vitiligo pricing should be roughly in the same ballpark as EPP on a per-patient value basis, despite different treatment patterns. On FDA engagement, CLINUVEL expects to meet the FDA after CUV105 top-line data and after CUV107 has started, with more data needed because the program is a drug-device combination. For NEURACTHEL, management said Europe comes first on a country-by-country basis, with the FDA following later, and said meaningful revenue timing depends on the EMA review process. On competition, management said EPP pressure in the U.S. looks temporary and that patients returning to SCENESSE suggests the market can support multiple entrants.